Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
3.
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
Gynecol Oncol
; 181: 155-161, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38176127
4.
Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol
; 187: 85-91, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735144
5.
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Gynecol Oncol
; 182: 7-14, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246047
6.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039991
7.
Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Int J Cancer
; 153(12): 2032-2044, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37602928
8.
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
Br J Cancer
; 129(11): 1841-1851, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37821637
9.
Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
BMC Cancer
; 23(1): 1014, 2023 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864152
10.
Comparison of oncological outcomes between sentinel lymph node biopsy and complete lymphadenectomy for endometrial cancer.
J Obstet Gynaecol Res
; 49(8): 2118-2125, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37286510
11.
Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
Gynecol Oncol
; 165(2): 369-375, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35277278
12.
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Gynecol Oncol
; 165(1): 97-104, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35153073
13.
Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
Gynecol Oncol
; 166(3): 438-443, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907682
14.
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Gynecol Oncol
; 167(2): 213-225, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192237
15.
Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
Gynecol Oncol
; 165(1): 75-81, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216810
16.
Anti-Obesity and Anti-Adipogenic Effects of Administration of Arginyl-Fructose-Enriched Jeju Barley (Hordeum vulgare L.) Extract in C57BL/6 Mice and in 3T3-L1 Preadipocytes Models.
Molecules
; 27(10)2022 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35630735
17.
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Mod Pathol
; 34(3): 637-646, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641744
18.
4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma.
Hepatology
; 71(3): 955-971, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31353502
19.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol
; 161(2): 502-507, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33612336
20.
Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Am J Obstet Gynecol
; 224(4): 370.e1-370.e13, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33039397